The announcement of Phase 2b topline data from the TREK-AD trial could potentially impact ASLAN Pharmaceuticals' stock. If the results are positive, it could boost the company's stock as it indicates progress in their product development. However, if the results are negative, it could lead to a decline in the stock price. The exact impact will depend on the results of the trial, hence the neutral score.